Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced.
Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed the outlook of this disease. However, its use in clinical practice raises important questions, such as who should receive the drug, when to start such therapy, and is it safe to stop treatment once the disease is controlled. We describe here for the 1sttime in India, use of eculizumab in a 12-year-old boy with aHUS. We also describe in this report challenges faced in procuring the drug, and an ideal, evidence-based method of treating aHUS in children.
Department of Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
S K
SK
Sethi
Department of Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
S
S
Rohatgi
INSERM UMRS 1138, Team 10 and Paris Descartes University, Paris, France.
M A
MA
Dragon-Durey
Pediatric Intensive Care, Medanta, The Medicity, Gurgaon, Haryana, India.
V
V
Raghunathan
Pediatric Intensive Care, Medanta, The Medicity, Gurgaon, Haryana, India.
M
M
Dhaliwal
Department of Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
A
A
Rawat
Department of Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
P
P
Jha
Department of Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
S B
SB
Bansal
Department of Pediatric Nephrology, Akron Children's Hospital, Cleveland, Ohio, USA.
R
R
Raina
Department of Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
V
V
Kher
Eculizumab; hemolytic uremic syndrome; plasma exchange; soliris